Agonistic antibody to DR4, such as Mapatumumab [24, 25, 26, 27, 28], and agonistic antibody to DR5, including Conatumumab [29, 30], Tigatuzumab [31, 32, 33], Drozitumab [34], Lexatumumab [35, 36], and LBY135 [37], have been evaluated in Phase 1 and/or 2 clinical trials as monotherapy or in combination for the treatment of various cancers. Here, TNFRSF10A is linked to cancer.